Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas

AKYERLİ BOYLU C., Yuksel S., CAN Ö., Erson-Omay E. Z., OKTAY Y., Cosgun E., ...Daha Fazla

JOURNAL OF NEUROSURGERY, cilt.128, sa.4, ss.1102-1114, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 128 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3171/2016.11.jns16973
  • Dergi Adı: JOURNAL OF NEUROSURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1102-1114
  • Anahtar Kelimeler: glioma, isocitrate dehydrogenase, telomerase, mutation, prognosis, oncology, ADULT MALIGNANT GLIOMAS, GENOMIC CHARACTERIZATION, NERVOUS-SYSTEM, GRADE GLIOMAS, TERT, GLIOBLASTOMA, TUMORS, PROGRESSION, SUBGROUPS, LANDSCAPE
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

OBJECTIVE Recent studies have established that hemispheric diffuse gliomas may be grouped into subsets on the basis of molecular markers; these subsets are loosely correlated with the histopathological diagnosis but are strong predictors of clinical tumor behavior. Based on an analysis of molecular and clinical parameters, the authors hypothesized that mutations of the telomerase promoter (TERTp-mut) mark separate oncogenic programs among isocitrate dehydrogenase 1 and/or 2 (IDH) mutant (IDH-mut) and IDH wild-type (IDH-wt) diffuse gliomas independent of histopathology or WHO grade.